Clinical Trial Search

Primary: Amyloid Burden — 1.20; 1.22; 1.21; 1.22 Standard Uptake Value Ratio (SUVR)

Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled

Primary: Number of Adverse Events — 355; 302 number of AEs

Primary: Changes in Global Cognitive Function Using Mini Mental State Examination Score (Post-study Test Score - Baseline Test Score) — -0.51; -0.07 score on a scale — p=0.25

Primary: Overall Score Changes From Baseline by Magnesium Treatment vs. Placebo — 1.1; 0.6 score on a scale — p=0.20

Primary: Cognitive Outcomes - Language Executive Function : Category Fluency Assessed as Number of Words Generated/Min — 21.5; 25.7 number of words generated per minute

Primary: Rey Auditory Verbal Learning Test Sum of Trials 1-5 — 49.7; 47.6; 51.6; 49.4 Sum of words recalled Trials 1 to 5

Primary: Assess Cognitive Efficacy in Individuals With Mutations Causing Dominantly Inherited AD as Measured by the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE); — 1.063…

Primary: Medication Appropriateness Index — 11.2; 9.4 units on a scale

Primary: Imaging Biomarkers FDG-PET SUVR in Regions of Interest — -0.048; -0.005; -0.032; -0.007 Standardized Uptake Value Ratios (SUVRs)

Primary: fMRI Measure of Hippocampal Activation — 36.4; 41.3 percentage of active voxels

Primary: California Verbal Learning Test II — 6.9; 6.2; 6.46; 5.10 units on a scale — p=0.048

Primary: Change From Baseline in ADAS-Cog Score — 1.39; 3.26 score on a scale — p=0.125

Primary: Mean Change in Cerebral Blood Flow as Measured by Magnetic Resonance Imaging (MRI) — 0.621528; 0.6447692; 0.654822667; 0.579838667 ml/110g/min

Primary: Time to Dispensing of Inappropriate Medication Prescription — 76.7; 77.9; 77.5 Percentage of Cumulative Incidence — p=0.76

Primary: Functional Connectivity Strengths of Neural Networks — 0.233; 0.318 Pearson coefficient — p=0.007567

Primary: Change in Amyloid Burden — -1.55 dSUVR

Primary: Number of Participants With a Decline of 6 Points on the Hopkins Verbal Learning Test-Revised (HVLT-R) — 1; 9 Participants — p=.02

Primary: Leisure Activities Questionnaire Activities Sum — 1.45; 4.45; 11.25 score on a scale — p=<0.05

Primary: Minutes of Moderate to Vigorous Physical Activity (MVPA) Per Day — 13.8; 17.9; 15.6; 21.8 min of MVPA/day

Primary: Short Form Health Survey (SF-36) — 48.4; 47.8; 48.8; 44.7 score on a scale

Primary: Total Step Count (Average Steps/Day) — 5648.91; 3809.62 Steps/day — p=<0.001

Primary: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks — 6.19; 7.29; 7.68 units on a scale — p=0.134

Primary: Change in East Boston Memory Test Scores From Baseline to 24 Weeks, 48 Weeks, and 72 Weeks — 0.03; -0.02; 0.01; 0.05 score on a scale — p=.409

Primary: Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks — 7.37; 6.77 units on a scale — p=0.560

Primary: Change From Baseline of the Preclinical Alzheimer Cognitive Composite (PACC) Score — -1.43; -1.13 score on a scale — p=0.260

Primary: Trails Making Test Part B (Executive Function) — 69.57; 81.59; 62.53; 69.25 time to completion (seconds)

Primary: Executive Function (EF). — 1.16; 0.99 z score

Primary: Number of Subjects Retained at 6 Months — 11; 4 Participants

Primary: Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. — 0.35; 0.20; 0.26; 0.32 z-score — p=0.3236